BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine

BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine - P&T Community

July 25, 2019

BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine P&T Community

ANN ARBOR, Mich., July 23, 2019 /PRNewswire/ -- BlueWillow Biologics today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the ...

RSV Treatment

BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine - P&T Community

Comments

Post a Comment

Popular posts from this blog

Analysis | The Keys to Speed in Race for Vaccine, and Its Perils - Washington Post

Prematurity Awareness Month: Educating the public about Respiratory Syncytial Virus is vital, claims leading consultant - ZAWYA

Oishei Children's Hospital Seeing Spike in RSV Cases - Spectrum News